SOUTH SAN FRANCISCO, Calif. , June 07, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the U.S.
SOUTH SAN FRANCISCO, Calif. , May 08, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and reported financial results for the
SOUTH SAN FRANCISCO, Calif. , April 27, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that four presentations regarding the company's
SOUTH SAN FRANCISCO, Calif. , April 20, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that the Markey Cancer Center at the University of
No Significant CA4P Drug Safety Issues Identified Initial Efficacy in Favor of CA4P, with 22% of CA4P Patients Responding versus 9% in the Control Arm Enrollment in the Study Continuing SOUTH SAN FRANCISCO, Calif. , April 18, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif. , March 31, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today announced that updates on several of its preclinical programs are
SOUTH SAN FRANCISCO, Calif. , March 30, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of orphan oncology indications, today provided a corporate update and announced 2016 financial
One patient of four (25%) achieved a complete remission No dose-limiting toxicities observed and study is progressing into the fourth dose cohort SOUTH SAN FRANCISCO, Calif. , March 15, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQX:MATN), a biopharmaceutical company developing vascular
In one study most animals receiving the combination of CA4P and anti-CTLA4 antibody were tumor free at completion Three additional studies provide evidence that CA4P may enhance anti-CTLA4, anti-PD1, and anti-PD-L1 antibody activity SOUTH SAN FRANCISCO, Calif. , Feb.
